MA28515B1 - Inhibiteurs de gsk-3 - Google Patents

Inhibiteurs de gsk-3

Info

Publication number: MA28515B1
Authority: MA; Morocco
Prior art keywords: gsk; inhibitors; compounds; thiadiazolidinc; alzheimer
Prior art date: 2004-04-05

Application number

MA29364A

Other languages

English (en)

Inventor

Gil Martinez

Diaz Isabel Dorronsoro

Cascon Mercedes Alonso

Pliego Gema Panizodel

Huerta Ana Fuertes

Puerto Maria Jose Perez

Padilla Miguel Medina

Original Assignee

Noscira Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-05

Filing date

2006-10-02

Publication date

2007-04-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28515(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-10-02 Application filed by Noscira Sa filed Critical Noscira Sa

2007-04-03 Publication of MA28515B1 publication Critical patent/MA28515B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Dermatology (AREA)
Epidemiology (AREA)

MA29364A 2004-04-05 2006-10-02 Inhibiteurs de gsk-3 MA28515B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04075997A EP1586318A1 (fr)	2004-04-05	2004-04-05	Thiazolidinones comme inhibiteurs de GSK-3

Publications (1)

Publication Number	Publication Date
MA28515B1 true MA28515B1 (fr)	2007-04-03

Family

ID=34928129

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA29364A MA28515B1 (fr)	2004-04-05	2006-10-02	Inhibiteurs de gsk-3

Country Status (29)

Country	Link
US (2)	US7531561B2 (fr)
EP (2)	EP1586318A1 (fr)
JP (1)	JP4995076B2 (fr)
KR (1)	KR101151647B1 (fr)
CN (1)	CN1946398B (fr)
AR (2)	AR048820A1 (fr)
AT (1)	ATE446090T1 (fr)
AU (1)	AU2005230392B2 (fr)
BR (1)	BRPI0508788A (fr)
CA (1)	CA2559740C (fr)
CY (1)	CY1109724T1 (fr)
DE (1)	DE602005017215D1 (fr)
DK (1)	DK1586319T3 (fr)
EC (1)	ECSP066858A (fr)
ES (1)	ES2335505T3 (fr)
HR (1)	HRP20100032T1 (fr)
IL (1)	IL178125A (fr)
MA (1)	MA28515B1 (fr)
MX (1)	MXPA06011194A (fr)
NO (1)	NO332751B1 (fr)
NZ (1)	NZ549904A (fr)
PL (1)	PL1586319T3 (fr)
PT (1)	PT1586319E (fr)
RS (1)	RS51340B (fr)
RU (1)	RU2379300C2 (fr)
SI (1)	SI1586319T1 (fr)
TW (1)	TWI352084B (fr)
WO (1)	WO2005097117A1 (fr)
ZA (1)	ZA200608221B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2408747C (fr)	2000-05-11	2011-04-05	Consejo Superior Investigaciones Cientificas	Inhibiteurs heterocycliques de la glycogene synthase kinase gsk-3
EP1586318A1 (fr) *	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiazolidinones comme inhibiteurs de GSK-3
WO2006045581A1 (fr) *	2004-10-21	2006-05-04	Neuropharma, S.A.	Utilisation de 1, 2, 4-thiadiazolidine-3, 5-diones en tant qu'activateurs de ppar
ES2258406B1 (es) *	2005-02-10	2007-12-01	Neuropharma, S.A.	Uso de compuestos heterociclicos como agentes neurogenicos.
EP1749523A1 (fr) *	2005-07-29	2007-02-07	Neuropharma, S.A.	Des inhibiteurs de GSK-3
CA2658263A1 (fr) *	2006-07-18	2008-01-24	University Of Rochester	Derives de thiadiazolidinone
WO2008012031A2 (fr) *	2006-07-25	2008-01-31	Universität Bern	Bloqueurs de gsk3 de prévention et de traitement de pemphigus vulgaire
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US8642598B2 (en)	2006-10-21	2014-02-04	Abbvie Inc.	Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
KR100837785B1 (ko) *	2007-01-17	2008-06-13	한국화학연구원	1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
KR100829468B1 (ko) *	2007-01-17	2008-05-16	한국화학연구원	신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2242745A1 (fr) *	2008-02-07	2010-10-27	Sanofi-Aventis	Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation
EP2310372B1 (fr)	2008-07-09	2012-05-23	Sanofi	Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
EP2177510A1 (fr)	2008-10-17	2010-04-21	Universität des Saarlandes	Modulateurs allostériques de protéine kinase
WO2010068601A1 (fr)	2008-12-08	2010-06-17	Sanofi-Aventis	Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
JP2013503135A (ja)	2009-08-26	2013-01-31	サノフイ	新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011151359A1 (fr) *	2010-06-02	2011-12-08	Noscira, S.A.	Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
WO2011157827A1 (fr)	2010-06-18	2011-12-22	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103119035B (zh)	2010-09-27	2015-09-30	雅培股份有限两合公司	杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
WO2012065065A1 (fr) *	2010-11-12	2012-05-18	Follica, Inc.	Procédés et compositions pour moduler la pousse de cheveux, la cicatrisation de plaie et la révision de cicatrice
WO2012078649A1 (fr)	2010-12-06	2012-06-14	Follica, Inc.	Procédés destinés à traiter la calvitie et à favoriser la croissance des cheveux
US9090592B2 (en)	2010-12-30	2015-07-28	AbbVie Deutschland GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683701B1 (fr)	2011-03-08	2014-12-24	Sanofi	Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (fr)	2011-03-08	2012-09-13	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2683700B1 (fr)	2011-03-08	2015-02-18	Sanofi	Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120052A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120051A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8865750B2 (en)	2011-04-28	2014-10-21	The Regents Of The University Of Michigan	Small molecule inhibitors of RGS proteins
EP2527323A1 (fr)	2011-05-24	2012-11-28	Noscira, S.A.	Dérivés de disulfure de carbonyle d'urée et leurs utilisations thérapeutiques
WO2012170657A1 (fr) *	2011-06-07	2012-12-13	Georgetown University	Ciblage de gsk-3 bêta pour le traitement de la maladie de parkinson
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr)	2011-09-27	2015-10-21	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
LT2838888T (lt) *	2012-02-24	2017-08-10	Asd Therapeutics Partners Llc	Tiadiazolidindionai kaip gsk-3 inhibitoriai
RU2509155C1 (ru) *	2012-10-25	2014-03-10	Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук	Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
CN103992312A (zh) *	2013-02-18	2014-08-20	江苏欧威医药有限公司	1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
CN103992313A (zh) *	2013-02-18	2014-08-20	江苏欧威医药有限公司	1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
WO2015075051A1 (fr)	2013-11-19	2015-05-28	Universitaet Des Saarlandes	Inhibiteurs allostériques de protéines kinases c atypiques
WO2015155738A2 (fr)	2014-04-09	2015-10-15	Christopher Rudd	Utilisation d'inhibiteurs ou d'activateurs de gsk -3 qui modulent l'expression de pd -1 ou de t-bet pour moduler l'immunité due aux lymphocytes t
WO2015192078A1 (fr) *	2014-06-12	2015-12-17	Cedars-Sinai Medical Center	Compositions et procédés de traitement de cancers
CN107151235B (zh) *	2016-03-04	2019-12-13	上海市计划生育科学研究所	噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
WO2017153834A1 (fr) *	2016-03-10	2017-09-14	Alma Mater Studiorum - Universitá Di Bologna	Traitement de troubles de cdkl5 avec tideglusib, inhibiteur de gsk3β
GB201617820D0 (en) *	2016-10-21	2016-12-07	King S College London	Dental treatment
US11590110B2 (en) *	2017-06-06	2023-02-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor
WO2021209563A1 (fr)	2020-04-16	2021-10-21	Som Innovation Biotech, S.A.	Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire
CN113827592B (zh) *	2020-06-24	2024-06-18	中国科学院上海药物研究所	一种噻二唑烷二酮基化合物在治疗致病性感染中的应用
CN116940356A (zh) *	2021-02-11	2023-10-24	文卡研究公司	用于治疗致心律失常性心肌病的组合物和方法
US20240173304A1 (en)	2021-02-24	2024-05-30	Teva Pharmaceuticals International Gmbh	Solid state forms of tideglusib and process for preparation thereof
EP4340832A1 (fr)	2021-05-21	2024-03-27	Amo Pharma Ltd.	Procédé de traitement de maladies à médiation par des répétitions d'arn ayant un composé de liaison de répétition d'arn
EP4094760A1 (fr)	2021-05-24	2022-11-30	Consejo Superior De Investigaciones Científicas	Thiadiazolidinones pour leur utilisation dans le traitement de la dystrophie scapulo-humérale
CN115197167B (zh) *	2022-07-22	2023-07-28	中国药科大学	1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
CN117986202B (zh) *	2024-04-03	2024-06-14	中国药科大学	具有ptpn2抑制活性的1，2，4-噻二唑烷-3，5-二酮化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2408747C (fr) *	2000-05-11	2011-04-05	Consejo Superior Investigaciones Cientificas	Inhibiteurs heterocycliques de la glycogene synthase kinase gsk-3
ES2166328B1 (es) *	2000-05-11	2003-09-16	Consejo Superior Investigacion	Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
EP1586318A1 (fr) *	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiazolidinones comme inhibiteurs de GSK-3

2004
- 2004-04-05 EP EP04075997A patent/EP1586318A1/fr not_active Withdrawn
2005
- 2005-04-01 AR ARP050101293A patent/AR048820A1/es not_active Application Discontinuation
- 2005-04-04 EP EP05075779A patent/EP1586319B1/fr not_active Expired - Lifetime
- 2005-04-04 RS RSP-2010/0017A patent/RS51340B/sr unknown
- 2005-04-04 PL PL05075779T patent/PL1586319T3/pl unknown
- 2005-04-04 ZA ZA200608221A patent/ZA200608221B/xx unknown
- 2005-04-04 RU RU2006139030/04A patent/RU2379300C2/ru active
- 2005-04-04 NZ NZ549904A patent/NZ549904A/en not_active IP Right Cessation
- 2005-04-04 DE DE602005017215T patent/DE602005017215D1/de not_active Expired - Lifetime
- 2005-04-04 DK DK05075779.8T patent/DK1586319T3/da active
- 2005-04-04 MX MXPA06011194A patent/MXPA06011194A/es active IP Right Grant
- 2005-04-04 CN CN2005800121414A patent/CN1946398B/zh not_active Expired - Lifetime
- 2005-04-04 TW TW094110769A patent/TWI352084B/zh not_active IP Right Cessation
- 2005-04-04 BR BRPI0508788-0A patent/BRPI0508788A/pt not_active IP Right Cessation
- 2005-04-04 ES ES05075779T patent/ES2335505T3/es not_active Expired - Lifetime
- 2005-04-04 WO PCT/EP2005/003613 patent/WO2005097117A1/fr not_active Ceased
- 2005-04-04 JP JP2007506716A patent/JP4995076B2/ja not_active Expired - Lifetime
- 2005-04-04 AU AU2005230392A patent/AU2005230392B2/en not_active Expired
- 2005-04-04 PT PT05075779T patent/PT1586319E/pt unknown
- 2005-04-04 CA CA2559740A patent/CA2559740C/fr not_active Expired - Lifetime
- 2005-04-04 SI SI200530879T patent/SI1586319T1/sl unknown
- 2005-04-04 AT AT05075779T patent/ATE446090T1/de active
- 2005-04-05 US US11/098,610 patent/US7531561B2/en not_active Expired - Lifetime
2006
- 2006-09-14 IL IL178125A patent/IL178125A/en active IP Right Grant
- 2006-09-18 EC EC2006006858A patent/ECSP066858A/es unknown
- 2006-10-02 MA MA29364A patent/MA28515B1/fr unknown
- 2006-10-02 NO NO20064456A patent/NO332751B1/no unknown
- 2006-10-11 KR KR1020067021121A patent/KR101151647B1/ko not_active Expired - Lifetime
2009
- 2009-04-22 US US12/428,442 patent/US8158661B2/en not_active Expired - Lifetime
2010
- 2010-01-13 CY CY20101100036T patent/CY1109724T1/el unknown
- 2010-01-18 HR HR20100032T patent/HRP20100032T1/hr unknown
2016
- 2016-04-27 AR ARP160101182A patent/AR104417A2/es unknown

Also Published As

Publication number	Publication date
AR104417A2 (es)	2017-07-19
CN1946398A (zh)	2007-04-11
IL178125A (en)	2012-01-31
JP2007531782A (ja)	2007-11-08
DE602005017215D1 (de)	2009-12-03
NO20064456L (no)	2006-10-02
PT1586319E (pt)	2010-01-21
NZ549904A (en)	2010-08-27
HRP20100032T1 (hr)	2010-03-31
JP4995076B2 (ja)	2012-08-08
AU2005230392B2 (en)	2011-03-24
AU2005230392A1 (en)	2005-10-20
EP1586319B1 (fr)	2009-10-21
ZA200608221B (en)	2008-08-27
SI1586319T1 (sl)	2010-02-26
US20090233971A1 (en)	2009-09-17
ATE446090T1 (de)	2009-11-15
NO332751B1 (no)	2013-01-07
RU2006139030A (ru)	2008-05-20
RS51340B (sr)	2011-02-28
CY1109724T1 (el)	2014-08-13
US8158661B2 (en)	2012-04-17
ES2335505T3 (es)	2010-03-29
MXPA06011194A (es)	2007-03-21
TW200538119A (en)	2005-12-01
US7531561B2 (en)	2009-05-12
IL178125A0 (en)	2006-12-31
WO2005097117A1 (fr)	2005-10-20
TWI352084B (en)	2011-11-11
AR048820A1 (es)	2006-05-31
KR101151647B1 (ko)	2012-06-08
BRPI0508788A (pt)	2007-09-04
ECSP066858A (es)	2007-01-26
US20050222220A1 (en)	2005-10-06
EP1586319A1 (fr)	2005-10-19
EP1586318A1 (fr)	2005-10-19
DK1586319T3 (da)	2010-02-08
PL1586319T3 (pl)	2010-06-30
RU2379300C2 (ru)	2010-01-20
CA2559740A1 (fr)	2005-10-20
HK1100426A1 (en)	2007-09-21
KR20060131976A (ko)	2006-12-20
CA2559740C (fr)	2014-06-10
CN1946398B (zh)	2011-03-30

Publication	Publication Date	Title
MA28515B1 (fr)	2007-04-03	Inhibiteurs de gsk-3
EA200901373A1 (ru)	2010-06-30	Аминогетероциклические соединения
DE602004028150D1 (de)	2010-08-26	Aminopyrazolderivate als gsk-3-inhibitoren
SV2006002055A (es)	2006-05-09	Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
MXPA03011484A (es)	2004-03-18	Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
SE0102299D0 (sv)	2001-06-26	Compounds
BRPI0417543A (pt)	2007-03-27	quinolinas úteis no tratamento de doença cardiovascular
EA200200716A1 (ru)	2003-02-27	Арилконденсированные азаполициклические соединения
CL2007002288A1 (es)	2008-02-08	Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro
CY1107956T1 (el)	2013-03-13	Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
ATE409480T1 (de)	2008-10-15	Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
UY30377A1 (es)	2008-01-02	Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
EA200601194A1 (ru)	2006-10-27	Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
EA200801184A1 (ru)	2008-08-29	Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
SG161217A1 (en)	2010-05-27	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
ATE403428T1 (de)	2008-08-15	Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EA200801134A1 (ru)	2009-02-27	Замещенные бициклические пиримидоновые производные
EP1817312A4 (fr)	2009-11-04	Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer
ATE420853T1 (de)	2009-01-15	5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung
DOP2005000049A (es)	2005-12-15	Compuestos de sulfonamidas para el tratamiento de trastornos neurodegererativos
DE602004019778D1 (de)	2009-04-16	Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
EA200701856A1 (ru)	2008-02-28	Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
ATE399758T1 (de)	2008-07-15	Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
UY28842A1 (es)	2005-10-31	Inhibidores de gsk-3
BRPI0606730A2 (pt)	2009-07-14	derivados de fenil metanona 2,5-di-substituìdos como inibidores do transportador de glicina 1 (glyt-1) para o tratamento de distúbios neurológicos e neuropsiquiátricos